Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7179-7183

  Sridhar, S ^a   Ali, A A ^a   Liang, Y ^a   El Etreby, M F ^a   Lewis, R W ^a   Kumar, M V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIGESTAGEN; CASPASE 8; CYTOTOXIC AGENT; MIFEPRISTONE; RECEPTOR; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MIFEPRISTONE; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035476850     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Molecular mechanisms of androgen action
2. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells
3. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation
4. Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl2 family members and caspase activation
5. Hormonal control of apoptosis: The rat prostate gland as a model system
6. Anti-apoptosis genes and the development of hormone-resistant prostate cancer
7. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer
8. Novel molecular targets for prostate cancer therapy
9. Chemotherapy of advanced prostatic carcinoma
10. An elevated bax/bcl2 ratio corresponds with the onset of prostate epithelial cell apoptosis
11. Drug development in prostate cancer
12. Progesterone antagonists in reproductive medicine and oncology
13. Antitumor activity of the progesterone antagonists ZK98.299 and RU38.486 in the hormone-dependent MXT-mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat
14. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models
15. Antitumor activity of the progesterone antagonists ZK98.299 and RU38.486 in hormone dependent rat and mouse mammary tumors: Mechanistic studies
16. 1
17. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI164384
18. Additive effect of Mifepristone and Tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells
19. Effect of antiprogestins and Tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice
20. RU 486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells
21. Inhibition of endometrial cancer cell lines by Mifepristone (RU 486)
22. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486
23. Mifeprisone. Auxiliary therapeutic use in cancer and related disorders
24. Regression of the decidualized mesometrium and decidual cell apoptosis are associated with a shift in expression of Bcl2 family members
25. Induction of apoptosis by Mifepristone and Tamoxifen in human LNCaP prostate cancer cells in culture
26. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics
27. Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling
28. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor receptor family
29. Death receptors: Signaling and modulation
30. Lethal effect of the anti-Fas antibody in mice
31. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
32. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
33. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor related apoptosis-inducing ligand in vitro and in vivo
34. Phase II study of the progesterone antagonist Mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada clinical trials group study
35. Phase II study of Mifepristone (RU486) in refractory ovarian cancer
36. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4 and LNCaP-C4-2 prostate cancer models in nude mice
37. Breaking the mitochondrial barrier